Fluicell AB (OSTO:FLUI) Stock Based Compensation: kr0.00 Mil (TTM As of Mar. 2026)


OSTO:FLUI Fluicell AB OSTO:FLUI
50 GF Score
Price kr36.00
GF Value kr34.34
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Fluicell AB Stock Based Compensation?

Fluicell AB OSTO:FLUI 50 Stock Based Compensation is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:FLUI with a GF Score™ of 50/100 and a GF Value™ of kr34.34 (Fairly Valued). The stock has 4 warning signs investors should review.

Fluicell AB's Stock Based Compensation for the three months ended in Mar. 2026 was kr0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Fluicell AB Stock Based Compensation Related Terms

Fluicell AB Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Fluicell AB's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fluicell AB Stock Based Compensation Chart

Fluicell AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Fluicell AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:FLUI
50GF Score
Fluicell AB OSTO:FLUI
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fluicell AB Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

What does a Stock Based Compensation of kr0.00 Mil mean?
Fluicell AB (OSTO:FLUI) has a Stock Based Compensation of kr0.00 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Fluicell AB and its competitors.
Is Fluicell AB's Stock Based Compensation too high?
Fluicell AB's current Stock Based Compensation is kr0.00 Mil. Overall, Fluicell AB has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Stock Based Compensation compare to VRTX and REGN?
Fluicell AB's Stock Based Compensation of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Fluicell AB and its competitors. Fluicell AB's current Stock Based Compensation is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Fairly Valued. The stock's GF Value™ is kr34.34, compared to a current price of kr36.00 — trading 4.8% above its estimated fair value. The current Stock Based Compensation is kr0.00 Mil. Fluicell AB's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current Stock Based Compensation is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?

Based on GuruFocus' analysis, Fluicell AB stock appears to be overvalued. The current stock price of kr36.00 is trading 4.8% above its estimated GF Value™ of kr34.34. GuruFocus considers Fluicell AB to be Fairly Valued.

Key valuation signals for OSTO:FLUI:

  • Stock Based Compensation: kr0.00 Mil
  • GF Value™: kr34.34 vs. price of kr36.00 (4.8% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fluicell AB Business Description

Other Exchanges 5J90:Germany
Address Flojelbergsgatan 8C, Molndal, Gothenburg, SWE, 431 37
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
50GF Score

Get the complete analysis for OSTO:FLUI

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr36.00
Price
kr34.34
GF Value